A new trading day began on Friday, with Avadel Pharmaceuticals plc (NASDAQ: AVDL) stock price down -26.10% from the previous day of trading, before settling in for the closing price of $10.69. AVDL’s price has ranged from $9.41 to $19.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -40.57%. Meanwhile, its annual earnings per share averaged 75.25%. With a float of $88.15 million, this company’s outstanding shares have now reached $96.34 million.
Considering the fact that the conglomerate employs 154 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 91.92%, operating margin of -46.33%, and the pretax margin is -52.84%.
Avadel Pharmaceuticals plc (AVDL) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Avadel Pharmaceuticals plc is 8.52%, while institutional ownership is 74.87%. The most recent insider transaction that took place on Dec 13 ’24, was worth 24,019. In this transaction Chief Financial Officer of this company bought 2,300 shares at a rate of $10.44, taking the stock ownership to the 87,800 shares. Before that another transaction happened on Dec 11 ’24, when Company’s Chief Financial Officer bought 5,000 for $10.49, making the entire transaction worth $52,432. This insider now owns 85,500 shares in total.
Avadel Pharmaceuticals plc (AVDL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.25% per share during the next fiscal year.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Trading Performance Indicators
Here are Avadel Pharmaceuticals plc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.77, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.17 in one year’s time.
Technical Analysis of Avadel Pharmaceuticals plc (AVDL)
Compared to the last year’s volume of 2.47 million, its volume of 2.78 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 30.69%. Additionally, its Average True Range was 0.72.
During the past 100 days, Avadel Pharmaceuticals plc’s (AVDL) raw stochastic average was set at 5.50%, which indicates a significant decrease from 12.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 128.60% in the past 14 days, which was higher than the 79.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.54, while its 200-day Moving Average is $14.46. Nevertheless, the first resistance level for the watch stands at $8.30 in the near term. At $8.69, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.15. If the price goes on to break the first support level at $7.45, it is likely to go to the next support level at $6.99. Should the price break the second support level, the third support level stands at $6.60.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Key Stats
With a market capitalization of 761.24 million, the company has a total of 96,362K Shares Outstanding. Currently, annual sales are 27,960 K while annual income is -160,280 K. The company’s previous quarter sales were 50,030 K while its latest quarter income was -2,630 K.
